GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biohaven Ltd (NYSE:BHVN) » Definitions » Debt-to-Equity

Biohaven (Biohaven) Debt-to-Equity : 0.10 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Biohaven Debt-to-Equity?

Biohaven's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $3.45 Mil. Biohaven's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $27.09 Mil. Biohaven's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $301.45 Mil. Biohaven's debt to equity for the quarter that ended in Mar. 2024 was 0.10.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Biohaven's Debt-to-Equity or its related term are showing as below:

BHVN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06   Med: 0.08   Max: 0.11
Current: 0.1

During the past 4 years, the highest Debt-to-Equity Ratio of Biohaven was 0.11. The lowest was 0.06. And the median was 0.08.

BHVN's Debt-to-Equity is ranked better than
58.61% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs BHVN: 0.10

Biohaven Debt-to-Equity Historical Data

The historical data trend for Biohaven's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Debt-to-Equity Chart

Biohaven Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
- 0.08 0.06 0.07

Biohaven Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.08 0.11 0.07 0.10

Competitive Comparison of Biohaven's Debt-to-Equity

For the Biotechnology subindustry, Biohaven's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biohaven's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biohaven's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Biohaven's Debt-to-Equity falls into.



Biohaven Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Biohaven's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Biohaven's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biohaven  (NYSE:BHVN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Biohaven Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Biohaven's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Biohaven (Biohaven) Business Description

Traded in Other Exchanges
N/A
Address
215 Church Street, New Haven, CT, USA, 06510
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on discovering and developing therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, immunology, and disease-related biology, including rare disorders. Its neuroscience portfolio includes a broad pipeline of drug candidates modulating distinct nervous system targets, including Kv7, glutamate receptors, myostatin, and TRP channels. Its products target diseases such as migraine, depression, bipolar, and schizophrenia.
Executives
Irina Antonijevic director 215 CHURCH STREET, NEW HAVEN CT 06510
John W Childs director 111 HUNTINGTON AVENUE, SUITE 2900, BOSTON MA 02199
Vlad Coric director, officer: Chief Executive Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Matthew Buten officer: Chief Financial Officer 215 CHURCH STREET, NEW HAVEN CT 06510
Gregory Bailey director 4 A CHESHAM STREET, LONDON X0 SW1X8DT
George C. Clark officer: VP, Chief Accounting Officer 215 CHURCH STREET, NEW HAVEN CT 06510
Julia P Gregory director 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Robert J Hugin director C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Kimberly Gentile officer: SVP, Clinical Operations C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Kishan Mehta director 540 WEST 49TH STREET, UNIT# PH1N, NEW YORK NY 10019
Biohaven Pharmaceutical Holding Co Ltd. 10 percent owner 215 CHURCH STREET, NEW HAVEN CT 06510
Bruce Car officer: Chief Scientific Officer AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139